The group's principal activity is to develop and market early-stage technologies. The activities include identifying development-stage biomedical, pharmaceutical, medical devices or other technologies that are commercially viable. The group intends to acquire proprietary rights to these technologies, fund its research and development and bring these technologies to market. The group has developed a technology that can be used in treating pain and inflammation. The group and its operating subsidiaries are in the development stage, concentrating on performing research and development activities. The group is developing its proprietary compound ct-3, a patented synthetic derivative of carboxylic tetrahydrocannabinol (thc-7c), as an alternative to nonsteroidal anti-inflammatory drugs, such as aspirin and ibuprofen. During the year 2003, the group completed a reverse acquisition of privately held manhattan research development inc.
